N;SPECIES_MDR1;NAME;CAS;SMILES;PARSED_SMILES;SUBST_SCORE;SUBST_DATA;INHIB_SCORE;INHIB_SCORE_TYPE;INHIB_DATA;INHIB_REF;EXPERIMENT;COMMENT;REFERENCE;INDUCER_SCORE;TARGET;class
2447;Human;1,4-Dihydropyridine;3337175;C1=CCC=CN1;C1NC=CCC=1;1.0;;;10uM;;;; (from review);PMID17346156;;BCRP;1
2449;Human;1-Methyl-6-phenyl-imidazo[4,5-b]pyridin-2-amine (PhIP);105650235;n1cc(cc2c1nc(n2C)N)c3ccccc3;N1=C3C(=CC(=C1)C2=CC=CC=C2)N(C(=N3)N)C;1.0;;;10uM;;;biliary and intestinal excretion ; ;"A. E. van Herwaarden, Cancer Res (2003) 63, 6447-52; PMID17346156";;BCRP;1
2450;Mouse;2,4-Dinitrophenyl-S-glutathione (DNP-SG);26289394;O=C(O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O;O=C(O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSC1=C(C=C(C=C1)N(=O)=O)N(=O)=O;1.0;;0.0;10uM;78% at 80mkM ;Estrone 3-sulfate;membrane vesicle from ABCG2-expressing P388 cell ;inhibition of E1S ;"M. Suzuki, J Biol Chem (2003) 278, 22644-9; PMID17346156";;BCRP;1
2454;Human;4-Methylumbelliferone glucuronide;6160801;OC(=O)[C@H]3O[C@@H](Oc1ccc2C(C)=CC(=O)Oc2c1)[C@H](O)[C@@H](O)[C@@H]3O;OC(=O)[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=CC3OC(C=C(C=3C=C2)C)=O)O)O)O;1.0;;0.0;10uM;"84% at 500mkM; 100% at 50mkM";"Estrone 3-sulfate; Mitoxantrone";"membrane vesicle from ABCG2-expressing P388 cell; Saos-2/wtABCG2 cells";"inhibition of E1S; ABCG2 (BCRP) Mitoxantrone accumulation";"M. Suzuki, J Biol Chem (2003) 278, 22644-9; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;1
2455;Human;4-Methylumbelliferone sulfate;15220118;O=S(=O)(O)Oc2ccc\1c(OC(=O)/C=C/1C)c2;O=S(=O)(O)OC1=CC2=C(C=C1)C(=C(/[H])C(=O)O2)\C;1.0;Km=13mkM ;1.0;10uM;IC50=6mkM;Estrone 3-sulfate;membrane vesicle from ABCG2-expressing mouse lymphoma(P388)cell ;uptake (vesicle) ;M. Suzuki, J Biol Chem (2003) 278, 22644-9 ;;BCRP;1
2464;Human;6-Hydroxy-5,7-dimetyl-2-metylamino-4-(3-pyridylmethyl) benzothiazole sulfate;157192079;c1ncccc1Cc2c(C)c(OS(=O)(=O)O)c(C)c3c2N=C(NC)S3;C1=C(C=CC=N1)CC2=C3C(=C(C(=C2C)OS(=O)(=O)O)C)SC(=N3)NC;1.0;Km=27mkM ;1.0;10uM;IC50=10mkM;Estrone 3-sulfate;membrane vesicle from ABCG2-expressing P388 cell ;uptake (vesicle) ;M. Suzuki, J Biol Chem (2003) 278, 22644-9 ;;BCRP;1
2465;Human;6-Prenyl-chrysin;50678916;Oc1c(CC=C(C)C)c(O)c2C(=O)C=C(Oc2c1)c3ccccc3;OC1=CC2OC(=CC(C=2C(=C1CC=C(C)C)O)=O)C3=CC=CC=C3;0.0; - [by ATPase];1.0;10uM;IC50=0.29mkM;Mitoxantrone;HEK293-transfected cells;drug resistance;"PMID17346156; A.Ahmed-Belkacem et al, Cancer Res (2005), 65(11), 4852-60";;BCRP;0
2475;Human;9-Aminocamptothecin;91421431;O=C1C5=C(C=C2N1CC3C=C4C(=NC2=3)C=CC=C4N)[C@@](C(OC5)=O)(O)CC;O=C1C5=C(C=C2N1CC3C=C4C(=NC2=3)C=CC=C4N)[C@@](C(OC5)=O)(O)CC;1.0;+ ;;10uM;;;T8 and MX3 cell ;"increase of cytotoxicity by GF120918; drug resistance (both WT and R482T)";"R.Rajendra et al, Cancer Res (2003), 63, 3228-3233; M. Maliepaard, Clin Cancer Res (2001) 7, 935-41 ";;BCRP;1
2476;Human;9-Nitrocamptothecin;91421420;O=N(=O)C1=C2C=C3C(=NC2=CC=C1)C4=CC5=C(C(N4C3)=O)COC(=O)[C@]5(O)CC;O=N(=O)C1=C2C=C3C(=NC2=CC=C1)C4=CC5=C(C(N4C3)=O)COC(=O)[C@]5(O)CC;0.0; -;;10uM;;;;"SYN: rubitecan; drug resistance (both WT and R482T)";"R.Rajendra et al, Cancer Res (2003), 63, 3228-3233; PMID17346156";;BCRP;0
2478;Human;Actinomycin D;50760;CC(C)[C@H]6NC(=O)[C@@H](NC(=O)c1ccc(C)c2O\C\3=C(/C)C(=O)C(\N)=C(C/3=N\c12)C(=O)N[C@@H]5C(=O)N[C@@H](C(=O)N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]5C)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]7CCCN7C6=O;CC(C)[C@@H]1C(N7CCC[C@H]7C(N(CC(N([C@H](C(O[C@@H]([C@@H](C(N1)=O)NC(=O)C2=C3\N=C4C(/OC3=C(C=C2)C)=C(/C)C(=O)C(N)=C/4C(=O)N[C@H]5[C@H](OC([C@@H](N(C(CN(C([C@@H]6CCCN6C([C@H](NC5=O)C(C)C)=O)=O)C)=O)C)C(C)C)=O)C)C)=O)C(C)C)C)=O)C)=O)=O;1.0;;;10uM;;;Cytotoxicity ; ;X. Wang, Mol Pharmacol (2003) 63, 65-72 ;;BCRP;1
2480;Human;Albendazole;54965218;O=C(OC)Nc2nc1ccc(SCCC)cc1n2;O=C(OC)NC1NC2=CC(=CC=C2N=1)SCCC;0.0; -;0.0;10uM;>85% at 50mkM;Mitoxantrone;BCRP-expressing MDCKII cells ;transepithelial transport (10mkM), inhibition;G. Merino, Drug Metab Dispos (2005) , 33(5), 614-618;;BCRP;0
2481;Human;Albendazole-sulphoxide;54029128;O=S(c2cc1c(nc(n1)NC(=O)OC)cc2)CCC;O=S(C1=CC=C2C(=C1)N=C(N2)NC(=O)OC)CCC;1.0; + (moderate substrate);0.0;10uM;71% at 375mkM;Mitoxantrone;BCRP-expressing MDCKII cells ;transepithelial transport (10mkM), transport inhibition (Mitoxantrone 5mkM);G. Merino, Drug Metab Dispos (2005) , 33(5), 614-618;;BCRP;1
2489;Human;Atorvastatin lactone;125995031;O=C(O5)C[C@H](O)C[C@H]5CCn2c(c(c(c2c1ccc(F)cc1)c3ccccc3)C(=O)Nc4ccccc4)C(C)C;O=C1O[C@@H](C[C@H](C1)O)CCN2C(=C(C(=C2C(C)C)C(=O)NC3=CC=CC=C3)C4=CC=CC=C4)C5=CC=C(C=C5)F;1.0;;1.0;10uM;Ki=14.3mkM;Estrone-3-sulfate;HEK293/BCRP membrane vesicles;uptake, transport inhibition (via ATPase activity);M.Hirano et al, Mol Pharm (2005) 68(3), 800-7;;BCRP;1
2491;Human;Baicalein;491678;O=C1c3c(O)c(O)c(O)cc3OC(=C1)c2ccccc2;O=C1C=C(OC2=CC(=C(C(=C12)O)O)O)C3=CC=CC=C3;0.2;(likely inactive);0.5;10uM; + at 30mkM;Mitoxantrone;MCF7/MX100 cells;accumulation studies;"W. Brand et al, Biomedicine & Pharmacotherapy 60 (2006) 508-519; S.Zhang et al, Biochem Pharmacol (2005), 70, 627-639";;BCRP;0
2492;Human;BBR 3390;225918898;O=C4c1c(ccc2c1c(nn2CCNCCO)c3ccccc34)NCCNCCO;O=C1C4=CC=CC=C4C3C2=C(C=CC(=C12)NCCNCCO)N(N=3)CCNCCO;1.0;;;10uM;;;; (from review);PMID17346156;;BCRP;1
2495;Human;Benzo(a)pyrene-3-sulfate;61996712;[O-]S(=O)(=O)Oc4ccc1ccc2c5ccccc5cc3ccc4c1c23;OS(=O)(=O)OC1=C2C=CC4=CC5=CC=CC=C5C3C=CC(C=C1)=C2C=34;1.0;;;10uM;;;Caco-2;transport inhibition;B.Ebert et al, Carcinogenesis (2005), 26(10), 1754-63;;BCRP;1
2496;Human;beta-Sitosterol;83465;O[C@@H]4C/C3=C/C[C@@H]1[C@H](CC[C@]2([C@H]1CC[C@@H]2[C@H](C)CC[C@@H](CC)C(C)C)C)[C@@]3(C)CC4;O[C@H]1CC[C@]2([C@@H]3[C@@H](C/C=C2/C1)[C@H]4[C@@](CC3)([C@H](CC4)[C@H](C)CC[C@@H](CC)C(C)C)C)C;0.0;- ;;10uM;;;lymphocyte from Mdr1a/b-/- mice ;Flow cytometry ;C. Albrecht, Biochim Biophys Acta (2002) 1567, 133-42 ;;BCRP;0
2497;Mouse;Bicalutamide;90357065;O=C(Nc1cc(c(C#N)cc1)C(F)(F)F)C(O)(C)CS(=O)(=O)c2ccc(F)cc2;O=C(NC1=CC=C(C(=C1)C(F)(F)F)C#N)C(O)(C)CS(=O)(=O)C2=CC=C(C=C2)F;1.0;;;10uM;;;transfected MDCK cells;;N.Colabufo et al, Eur J Pharmacol (2008) 601, 38-42;;BCRP;1
2500;Human;Bisantrene;78186342;N(=C/c3c1ccccc1c(\C=N\NC/2=N/CCN\2)c4ccccc34)\N/C5=N/CCN5;N(/N\C1NCC\N=1)=C(/[H])C2=C5C=CC=CC5=C(C3=CC=CC=C23)C(/[H])=N\N/C4NCC\N=4;1.0;;;10uM;;;BCRP-expressing MEF3.8 cell ;drug resistance ;J. D. Allen, Cancer Res (2003) 63, 1339-44 ;;BCRP;1
2501;Mouse;BNP-1350;203923891;O=C1C5=C(C=C2N1CC3C(=C4C(=NC2=3)C=CC=C4)CC[Si](C)(C)C)[C@@](C(OC5)=O)(O)CC;O=C1C5=C(C=C2N1CC3C(=C4C(=NC2=3)C=CC=C4)CC[Si](C)(C)C)[C@@](C(OC5)=O)(O)CC;0.0;;;10uM;;Topotecan;T8 and MX3 cell ;drug resistance;"M. Maliepaard, Clin Cancer Res (2001) 7, 935-41; PMID17346156";;BCRP;0
2502;;Bodipy-FL-Prazosin;175799936;N1(CCN(CC1)C(=O)CCC2=CC=C(N2B(F)F)C=C3C(C)=CC(C)=N3)c4nc(N)c5cc(OC)c(OC)cc5n4;N1(CCN(CC1)C(=O)CCC2N(C(=CC=2)C=C3N=C(C=C3C)C)B(F)F)C4=NC5=CC(=C(C=C5C(=N4)N)OC)OC;1.0;;;10uM;;;; (from review);PMID17346156;;BCRP;1
2506;Human;C6-NBD-phosphatidylcholine;148533260;O=P([O-])(OCC[N+](C)(C)C)OC[C@H](OC(=O)CCCCCNC1=CC=C(N(=O)=O)C2=NON=C12)COC(=O)CCCCCCCCCCCCC;O=P(O)(OCC[N+](C)(C)C)OC[C@H](OC(=O)CCCCCNC1C2=NON=C2C(=CC=1)N(=O)=O)COC(=O)CCCCCCCCCCCCC;1.0;;;10uM;;;BCRP-expressing EPG85-257 cell ;efflux ;H. Woehlecke, Biochem J (2003) 376, 489-95 ;;BCRP;1
2507;Human;C6-NBD-phosphatidylserine;106918610;O=C(O[C@@H](COP(O)(=O)OC[C@H](N)C(O)=O)COC(=O)CCCCCNC1=CC=C(N(=O)=O)C2=NON=C12)CCCCCCCCCCCCCCC;O=C(O[C@@H](COP(O)(=O)OC[C@H](N)C(O)=O)COC(=O)CCCCCNC1C2=NON=C2C(=CC=1)N(=O)=O)CCCCCCCCCCCCCCC;1.0;;;10uM;;;BCRP-expressing EPG85-257 cell ;efflux ;H. Woehlecke, Biochem J (2003) 376, 489-95 ;;BCRP;1
2508;Human;Calcein;1461150;O=C(O)CN(CC(=O)O)Cc5cc4c(Oc1cc(O)c(cc1C34OC(=O)c2c3cccc2)CN(CC(=O)O)CC(=O)O)cc5O;O=C(O)CN(CC(=O)O)CC1=C(C=C2C(=C1)C4(C3C=C(C(=CC=3O2)O)CN(CC(=O)O)CC(=O)O)C5C(C(O4)=O)=CC=CC=5)O;0.0; -;;10uM;;;;;N.Colabufo et al, Eur J Pharmacol (2008) 601, 38-42;;BCRP;0
2509;Human;Calcein-AM;148504341;CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)Cc1cc5c(cc1OC(C)=O)Oc2cc(OC(C)=O)c(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)cc2C45OC(=O)c3ccccc34;CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)CC1=C(C=C2C(=C1)C4(C3C=C(C(=CC=3O2)OC(C)=O)CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)C5C=CC=CC=5C(O4)=O)OC(C)=O;1.0; +;;10uM;;;;;N.Colabufo et al, Eur J Pharmacol (2008) 601, 38-42;;BCRP;1
2510;Human;Camptothecin;7689034;CCC2(O)C(OCC3C(=O)N1Cc4cc5ccccc5nc4C1=CC2=3)=O;CCC1(C2C=C3C4=NC5=CC=CC=C5C=C4CN3C(C=2COC1=O)=O)O;0.0;- ;;10uM;;;;"drug resistance (discussion); review";"R.Rajendra et al, Cancer Res (2003), 63, 3228-3233; PMID17346156";;BCRP;0
2516;Human;Cerivastatin (acid);145599866;O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(nc(c(c1c2ccc(F)cc2)COC)C(C)C)C(C)C;O=C(O)C[C@H](O)C[C@H](O)/C=C(\[H])C1C(=C(C(=NC=1C(C)C)C(C)C)COC)C2=CC=C(C=C2)F;1.0;"(+) ; (+ in Human, - in Mouse)";1.0;10uM;Ki=18.1mkM;Estrone-3-sulfate;"OATP1B1/BCRP double transfected MDCKII cell; HEK293/BCRP membrane vesicles";"Transepithelical Transport (basal to apical); transport inhibition by ATPase";"S. Matsushima et al, J Pharmacol Exp Ther (2005) 314, 1059-67; M.Hirano et al, Mol Pharm (2005) 68(3), 800-7";;BCRP;1
2542;Human;Cholesterol;57885;O[C@@H]4C/C3=C/C[C@@H]1[C@H](CC[C@]2([C@H]1CC[C@@H]2[C@H](C)CCCC(C)C)C)[C@@]3(C)CC4;O[C@H]1CC[C@]2([C@@H]3[C@@H](C/C=C2/C1)[C@H]4[C@@](CC3)([C@H](CC4)[C@H](C)CCCC(C)C)C)C;1.0;;;10uM;;;membrane vesicle from BCRP-expressing Lactococcus lactis cell ;ATPase assay ;T. Janvilisri, J Biol Chem (2003) 278, 20645-51 ;;BCRP;1
2544;Human;CI 1033;289499452;Cl.Cl.Fc1ccc(cc1Cl)Nc4ncnc3cc(OCCCN2CCOCC2)c(NC(=O)\C=C)cc34;FC1=C(C=C(C=C1)NC2=C3C=C(C(=CC3=NC=N2)OCCCN4CCOCC4)NC(C=C)=O)[Cl];1.0;;;10uM;;;; (from review);PMID17346156;;BCRP;1
2546;Human;Cimetidine;51481619;CC1N=CNC=1CSCCNC(=NC#N)NC;CC1=C(NC=N1)CSCCNC(=NC#N)NC;1.0;;0.0;10uM;1.1-fold increase at 50mkM (99% at 50mkM);Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM);"P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; PMID17346156; M.Hirano et al, Mol Pharm (2005) 68(3), 800-7";;BCRP;1
2553;Human;Daunorubicin (Daunomycin);20830813;CC(=O)C2(O)CC(OC1CC(N)C(O)C(C)O1)c3c(O)c4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C2;CC(=O)C1(CC3C(=C4C(C5=CC=CC(=C5C(C4=C(C=3C(C1)OC2OC(C(C(C2)N)O)C)O)=O)OC)=O)O)O;1.0;Kact=2.5mkM ;0.0;10uM;IC50=59mkM;Estrone 3-sulfate;membrane vesicle from BCRP-expressing Sf9 cell ;"ATP hydrolysis; NB transported by mutant R482T protein only (e.g. MCF7 cells)!";"C. Ozvegy, Biochem Biophys Res Commun (2001) 285, 111-7; M. Suzuki, J Biol Chem (2003) 278, 22644-9; H.Minderman et al, Clinical Cancer Research (2004), 10, 1826-34";;BCRP;1
2554;Human;Dehydroepiandrosterone;53430;CC34CCC1C(CC=C2CC(O)CCC12C)C4CCC3=O;CC14C(C2C(CC1)C3(CCC(CC3=CC2)O)C)CCC4=O;1.0;;;10uM;;;;" (from review); SYN: DHEA";PMID17346156;;BCRP;1
2555;;Dehydroepiandrosterone-3-sulfate;651489;O=S(=O)(O)O[C@@H]4C/C3=C/C[C@@H]2[C@H](CC[C@@]1(C(=O)CC[C@H]12)C)[C@@]3(C)CC4;O=S(=O)(O)O[C@H]1CC[C@]2([C@@H]3[C@@H](C/C=C2/C1)[C@@H]4CCC([C@@]4(CC3)C)=O)C;1.0;;0.0;10uM;"50% at 30mkM; IC50=55mkM; 103% at 50mkM";"Estrone 3-sulfate; Estrone 3-sulfate; Mitoxantrone";"membrane vesicle from BCRP-expressing K562 cell; Saos-2/wtABCG2 cells";"SYN: DHEAS; inhibition of E1S; ABCG2 (BCRP) Mitoxantrone accumulation";"Y. Imai, Mol Pharmacol (2003) 64, 610-8; M. Suzuki, J Biol Chem (2003) 278, 22644-9; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;1
2562;Human;Diflomotecan;220997977;Fc2cc1cc5c(nc1cc2F)C=3N(C(=O)C4=C(C=3)[C@](O)(CC(=O)OC4)CC)C5;FC1C(=CC2=NC3=C(C=C2C=1)CN4C3=CC5=C(C4=O)COC(C[C@@]5(O)CC)=O)F;1.0;;;10uM;;;;;M.Hirano et al, Mol Pharm (2005) 68(3), 800-7;;BCRP;1
2568;Human;Doxorubicin;23214928;OCC(=O)C2(O)CC(OC1CC(N)C(O)C(C)O1)c3c(O)c4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C2;OCC(=O)C1(CC3C(=C4C(C5=CC=CC(=C5C(C4=C(C=3C(C1)OC2OC(C(C(C2)N)O)C)O)=O)OC)=O)O)O;1.0;Kact=5mkM ;0.0;10uM;72% at 1000mkM ;Estrone 3-sulfate;membrane vesicle from BCRP-expressing Sf9 cell ;"SYN: Adriamycin; STEREOISOMER: epirubicin; ATP hydrolysis ";"C. Ozvegy, Biochem Biophys Res Commun (2001) 285, 111-7; M. Suzuki, J Biol Chem (2003) 278, 22644-9 ";;BCRP;1
2569;Human;Exatecan;169869903;O.O.CS(O)(=O)=O.NC6CCc2c3c6c4CN/1C(=O)C=5COC(=O)C(O)(CC)C=5\C=C\1c4nc3cc(F)c2C;NC1C2=C6C(CC1)=C(C(=CC6=NC3\C4N(CC2=3)C(=O)C5=C(C=4(/[H]))C(C(OC5)=O)(O)CC)F)C;0.1;"poor substrate; - (review)";;10uM;;;T8 and MX3 cell ;"SYN: DX-9851F; increase of cytotoxicity by GF120918";"M. Maliepaard, Clin Cancer Res (2001) 7, 935-41; PMID17346156";;BCRP;0
2570;Human;E3040 glucuronide;157192080;c1ncccc1Cc2c(C)c(OC4OC(C(=O)O)C(O)C(O)C4O)c(C)c3c2N=C(NC)S3;C1=C(C=CC=N1)CC2=C4C(=C(C(=C2C)OC3C(C(C(C(O3)C(=O)O)O)O)O)C)SC(=N4)NC;1.0;;0.0;10uM;76% at 250mkM ;Estrone 3-sulfate;membrane vesicle from ABCG2-expressing P388 cell ;inhibition of E1S ;M. Suzuki, J Biol Chem (2003) 278, 22644-9 ;;BCRP;1
2577;Human;Estradiol-17beta-D-glucuronide;15270301;O=C(O)[C@H]5O[C@@H](Oc1ccc2c(c1)CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@H]23)[C@H](O)[C@@H](O)[C@@H]5O;O=C(O)[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=CC3=C(C=C2)[C@H]4CC[C@]5([C@H](CC[C@H]5[C@H]4CC3)O)C)O)O)O;0.8;(+) ;;10uM;;;OATP1B1/BCRP double transfected MDCKII cell ;Transepithelical Transport (basal to apical) ;S. Matsushima, J Pharmacol Exp Ther (2005) 314, 1059-67 ;;BCRP;1
2578;human;Estradiol-3-sulfate;481969;O=S(=O)(O)Oc1cc3c(cc1)[C@H]2CC[C@@]4([C@@H](O)CC[C@H]4[C@@H]2CC3)C;O=S(=O)(O)OC1=CC=C2C(=C1)CC[C@@H]3[C@@H]4CC[C@@H]([C@@]4(CC[C@H]23)C)O;1.0;;0.5;10uM;50% at 30mkM;Estrone 3-sulfate;membrane vesicle from BCRP-expressing K562 cell ;inhibition of E1S ;Y. Imai, Mol Pharmacol (2003) 64, 610-8 ;;BCRP;1
2580;Human;Estrone-3-sulfate;481970;O=S(=O)(O)Oc1cc4c(cc1)[C@H]3CC[C@@]2(C(=O)CC[C@H]2[C@@H]3CC4)C;O=S(=O)(O)OC1=CC=C2C(=C1)CC[C@@H]3[C@@H]4CCC([C@@]4(CC[C@H]23)C)=O;1.0;"Km=17mkM; Km=6.8mkM";1.0;10uM; + at 10mkM;Estrone-3-sulfate;"membrane vesicle from ABCG2-expressing P388 cell; HEK293/BCRP membrane vesicles, MDCKII/BCRP";"uptake (vesicle); uptake inhibition (50nM of [3H]estrone-3-sulfate)";"M. Suzuki, J Biol Chem (2003) 278, 22644-9; Y. Imai, Mol Pharmacol (2003) 64, 610-8; PMID17346156; M.Hirano et al, Mol Pharm (2005) 68(3), 800-7";;BCRP;1
2581;Human;Ethidium bromide;1239458;[Br-].c4c3c1ccc(cc1c(c2ccccc2)[n+](c3cc(N)c4)CC)N;C1=CC(=CC2=[N+](C(=C3C=C(C=CC3=C12)N)C4=CC=CC=C4)CC)N;1.0;;;10uM;;;BCRP-expressing Lactococcus lactis cell ;uptake ;T. Janvilisri, J Biol Chem (2003) 278, 20645-51 ;;BCRP;1
2583;Human;Etoposide (VP-16);33419420;COc7cc(C4C1C(COC1=O)C(OC2OC3COC(C)OC3C(O)C2O)c5cc6OCOc6cc45)cc(OC)c7O;COC1=C(C(=CC(=C1)C2C6C=C7OCOC7=CC=6C(C3C2C(OC3)=O)OC4C(C(C5OC(OCC5O4)C)O)O)OC)O;1.0;;0.0;10uM;1.3-fold increase at 50mkM (96% at 50mkM);Mitoxantrone;Saos-2/wtABCG2 cells;"Cytotoxicity; ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM)";"X. Wang, Mol Pharmacol (2003) 63, 65-72; PMID17346156; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30";;BCRP;1
2585;Human;Fenbendazole;43210679;O=C(OC)Nc3nc2ccc(Sc1ccccc1)cc2n3;O=C(OC)NC1NC2=CC(=CC=C2N=1)SC3=CC=CC=C3;0.0; -;0.0;10uM;>85% at 50mkM;Mitoxantrone;BCRP-expressing MDCKII cells ;transepithelial transport (10mkM), inhibition;G. Merino, Drug Metab Dispos (2005) , 33(5), 614-618;;BCRP;0
2592;Human;Flavopiridol;146426406;Clc4ccccc4C=2Oc1c(c(O)cc(O)c1C(=O)C=2)[C@@H]3CCN(C)C[C@@H]3O;[Cl]C1=C(C=CC=C1)C2=CC(C3=C(C=C(C(=C3O2)[C@H]4[C@H](CN(CC4)C)O)O)O)=O;1.0;;;10uM;;;;"drug resistance; correlation hBCRPmRNA with flavopiridol induced apoptosis ";T. Nakanishi, Clin Cancer Res (2003) 9, 3320-8 ;;BCRP;1
2595;Human;Fluticasone propionate;80474142;O=C(SCF)[C@]3(OC(=O)CC)[C@]2(C[C@H](O)[C@]4(F)[C@@]1(C(=CC(=O)C=C1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C;O=C(SCF)[C@]3(OC(=O)CC)[C@]2(C[C@H](O)[C@]4(F)[C@@]1(C(=CC(=O)C=C1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C;0.0; - at 5mkM [by ATPase];0.0;10uM; - at 10mkM;Mitoxantrone;MCF7/MR cells;efflux inhibition (5mkM of Mitoxantrone, 40min time);H.Cooray et al, European Journal of Pharmacology (2006) 531, 25-33;;BCRP;0
2596;Human;Fluvastatin;93957541;O=C(O)C[C@H](O)C[C@H](O)/C=C/c2c(c1ccccc1n2C(C)C)c3ccc(F)cc3;O=C(O)C[C@H](O)C[C@H](O)/C=C(\[H])C1N(C3=CC=CC=C3C=1C2=CC=C(C=C2)F)C(C)C;1.0;;1.0;10uM;Ki=5.43mkM;Estrone-3-sulfate;HEK293/BCRP membrane vesicles;uptake, transport inhibition (via ATPase activity);M.Hirano et al, Mol Pharm (2005) 68(3), 800-7;;BCRP;1
2597;Human;Folate;59303;O=C(O)[C@@H](NC(=O)C1=CC=C(C=C1)NCC2=CN=C3C(=N2)C(N=C(N3)N)=O)CCC(=O)O;O=C(O)[C@@H](NC(=O)C1=CC=C(C=C1)NCC2=CN=C3C(=N2)C(N=C(N3)N)=O)CCC(=O)O;1.0;;0.0;10uM;1.2-fold increase at 50mkM;Mitoxantrone;"membrane vesicle from ABCG2-R482-expressing HEK293 cell; Saos-2/wtABCG2 cells";"uptake (vesicle); ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM)";"Z. S. Chen, Cancer Res (2003) 63, 4048-54; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30";;BCRP;1
2603;Human;Gefitinib (ZD1839);184475352;Fc1ccc(cc1Cl)Nc4ncnc3c4cc(OCCCN2CCOCC2)c(OC)c3;FC1=C(C=C(C=C1)NC2=C3C(=NC=N2)C=C(C(=C3)OCCCN4CCOCC4)OC)[Cl];1.0;;1.0;10uM;"IC50=0.4mkM; 8-fold increase at 50mkM (0% at 50mkM); IC50=1.10mkM; IC50=1.26mkM";" -; Mitoxantrone; Hoechst 33342; Pheophorbide alpha";"BCRP-expressing Sf9 cell; Saos-2/wtABCG2 cells; MCF7/MX and MDCK/BCRP";"efflux of Hoechst33344; ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM); Inhibition of Hoechst 33342 (5mkM) and PhA (0.5mkM) transport";"C. Ozvegy-Laczka, Mol Pharmacol (2004) 65, 1485-95; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; K.Noguchi et al, Cancer Sci. 2009 Sep;100(9):1701-7; K.Yanase et al, Mol Cancer Ther (2004) 3(9), 1119; A.Pick et al, Bioor Med Chem Lett(2010), 20(1), 180-3";;BCRP;1
2604;Human;Genistein;446720;Oc1cc(O)c2C(=O)C(=COc2c1)c3ccc(O)cc3;OC1=CC2OC=C(C(C=2C(=C1)O)=O)C3=CC=C(C=C3)O;1.0;;1.0;10uM;"IC50=24mkM; + at 3mkM (+ at 1mkM); 42% at 50mkM";"Mitoxantrone; SN-38; Mitoxantrone";"BCRP-expressing K562 cell; HEK293-transfected cells; Saos-2/wtABCG2 cells";"cell accumulation; drug resistance; ABCG2 (BCRP) Mitoxantrone accumulation";"Y. Imai, Cancer Res (2004) 64, 4346-52; PMID17346156; A.Ahmed-Belkacem et al, Cancer Res (2005), 65(11), 4852-60; K.Katayama et al, Cancer Chemother Pharmacol (2007) 60, 789-797; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;1
2607;Human;Glyburide;10238218;COc3ccc(Cl)cc3C(NCCc2ccc(S(NC(=O)NC1CCCCC1)(=O)=O)cc2)=O;COC1=C(C=C(C=C1)[Cl])C(NCCC2=CC=C(C=C2)S(NC(=O)NC3CCCCC3)(=O)=O)=O;1.0;;0.5;10uM;"IC50=150mkM; 7.4-fold at 50mkM (8% at 50mkM)";" -; Mitoxantrone";"BCRP-expressing MCF7-MX cells; Saos-2/wtABCG2 cells";"inhibition of mitoxantrone efflux; ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM); SYN: Glibenclamide";"C. Gedeon, Placenta (2006) 27, 1096-102; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30";;BCRP;1
2608;Human;GV 196771;166974227;c1ccccc1N2CCC\(C2=O)=C\C3=C(C(=O)O)NC4=C3C(Cl)=CC(Cl)=C4;C1=C(C=CC=C1)N2C(C(/CC2)=C(/[H])C3C4=C(NC=3C(=O)O)C=C(C=C4[Cl])[Cl])=O;1.0;;;10uM;;;; (from review);PMID17346156;;BCRP;1
2610;Human;Hoechst 33342;23491523;CCOc6ccc(C4Nc5ccc(C2Nc3ccc(N1CCN(C)CC1)cc3N=2)cc5N=4)cc6;CCOC1=CC=C(C=C1)C2=NC3=CC(=CC=C3N2)C4=NC5=CC(=CC=C5N4)N6CCN(CC6)C;1.0;+ ;0.5;10uM;3.7-fold increase at 50mkM (40% at 50mkM);Mitoxantrone;"BCRP-expressing MCF-7 cell; Saos-2/wtABCG2 cells";"efflux; ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM); substrate of both, mutant and wild-type forms";"M. Kim, Clin Cancer Res (2002) 8, 22-8; PMID17346156; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; Y.Han et al, Eur J Pharm Sci (2008) 35, 30-41";;BCRP;1
2613;Human;Idarubicin;58957929;O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@@](O)(C(=O)C)C[C@@H]5O[C@@H]4O[C@H]([C@@H](O)[C@@H](N)C4)C;O=C1C5=CC=CC=C5C(C2=C(C3=C(C(=C12)O)[C@H](C[C@@](C3)(O)C(=O)C)O[C@H]4C[C@@H]([C@@H]([C@@H](O4)C)O)N)O)=O;0.0;;;10uM;;;;drug resistance ;PMID17346156;;BCRP;0
2614;Human;Imatinib (STI-571);152459955;O=C(Nc3ccc(c(Nc2nc(c1cccnc1)ccn2)c3)C)c4ccc(cc4)CN5CCN(CC5)C;O=C(NC1=CC(=C(C=C1)C)NC2=NC=CC(=N2)C3C=NC=CC=3)C4=CC=C(C=C4)CN5CCN(CC5)C;1.0;;1.0;10uM;"IC50=0.9mkM; IC50=0.5mkM; 8-fold increase at 50mkM (0% at 50mkM); IC50=4.07mkM; IC50=3.88mkM";" -; Hoechst 33342; Mitoxantrone; Hoechst 33342; Pheophorbide alpha";"BCRP-expressing HEK cell; BCRP-expressing Sf9 cell; Saos-2/wtABCG2 cells; MCF7/MX and MDCK/BCRP";"uptake; ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM); efflux of Hoechst33342; Inhibition of Hoechst 33342 (5mkM) and PhA (0.5mkM) transport";"H. Burger, Blood (2004), 104(9), 2940-2942; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; C. Ozvegy-Laczka, Mol Pharmacol (2004) 65, 1485-95; ; K.Noguchi et al, Cancer Sci. 2009 Sep;100(9):1701-7; A.Pick et al, Bioor Med Chem Lett(2010), 20(1), 180-3";;BCRP;1
2615;Human;Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (KP1019);124875203;Cl[Ru](Cl)(Cl)(Cl)(N1N=C2C=CC=CC2=C1)N1N=C2C=CC=CC2=C1;[Cl][Ru]([Cl])([Cl])([Cl])(N1C=C2C=CC=CC2=N1)N3C=C4C=CC=CC4=N3;0.0;;;10uM;;;HL60/vinc cell ;drug resistance;P. Heffeter, J Pharmacol Exp Ther (2004) , ;;BCRP;0
2617;Human;Irinotecan (CPT-11);97682445;O=C1[C@](C2C=C3N(C(C=2CO1)=O)CC4C(=C5C(=NC3=4)C=CC(=C5)OC(=O)N6CCC(CC6)N7CCCCC7)CC)(O)CC;O=C1[C@](C2C=C3N(C(C=2CO1)=O)CC4C(=C5C(=NC3=4)C=CC(=C5)OC(=O)N6CCC(CC6)N7CCCCC7)CC)(O)CC;1.0;+ ;;10uM;;;T8 and MX3 cell ;increase of cytotoxicity by GF120918 ;M. Maliepaard, Clin Cancer Res (2001) 7, 935-41 ;;BCRP;1
2618;Human;Isoquercitrin;21637252;O=C3c4c(O)cc(O)cc4OC(c1ccc(O)c(O)c1)=C3O[C@@H]2O[C@H]([C@H](O)CO)[C@H](O)[C@H]2O;O=C1C(=C(OC2=CC(=CC(=C12)O)O)C3=CC(=C(C=C3)O)O)O[C@H]4[C@@H]([C@H]([C@H](O4)[C@H](O)CO)O)O;0.2;(likely inactive);0.2;10uM;(likely inactive);;; (from review);W. Brand et al, Biomedicine & Pharmacotherapy 60 (2006) 508-519;;BCRP;0
2620;Human;J-107088;174402325;O=C2c1c6c(c4c(c1C(=O)N2NC(CO)CO)c3ccc(O)cc3n4)n(c5cc(O)ccc56)C7O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)CO;O=C1N(C(C2=C6C(=C3C(=C12)C5=CC=C(C=C5N3C4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)NC7=CC(=CC=C67)O)=O)NC(CO)CO;1.0;+ ;;10uM;;;BCRP-transfected PC-13 cell ;intracellular accumulation ;H. Komatani, Cancer Res (2001) 61, 2827-32 ;;BCRP;1
2621;Human;JAI-51;1184301641;CN1C2=C(C=CC=C2)C(=C1)C=CC(=O)C3=C(OC)C=C(OC)C=C3OC;CN1C2=C(C=CC=C2)C(=C1)C=CC(=O)C3=C(OC)C=C(OC)C=C3OC;0.0; -;1.0;10uM; + at 10mkM;Mitoxantrone;HCT116R cell;drug resistance;A.Boumendjel et al, BMC Cancer (2009), 9:242;;BCRP;0
2630;Human;Lamivudine;134678174;O=C1N=C(N)C=CN1[C@@H]2O[C@@H](SC2)CO;O=C1N=C(N)C=CN1[C@H]2CS[C@H](O2)CO;1.0;;0.0;10uM; - at 10-1000mkM;Pheophorbide alpha;"Anti-HIV-1 activity; MDCKII-BCRP";Pheophorbide (1mkM, 1h preincubation) flow cytometry efflux inhibition;"X. Wang, Mol Pharmacol (2003) 63, 65-72; J.Weiss et al, J Antimicrob Chemother(2007), 59(2), 238-245";;BCRP;1
2632;Human;Levodopa;59927;O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1;O=C(O)[C@@H](N)CC1=CC=C(C(=C1)O)O;0.05;(imputed as non-binder from inhibition data);0.0;10uM;0.9-fold increase at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM),  (from review);P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30;;BCRP;0
2638;Human;Lysotracker Green;220524710;CN(C)CCNC(=O)CCC1=CC=C(N1B(F)F)C=C2C(C)=CC(C)=N2;CN(C)CCNC(=O)CCC1N(C(=CC=1)C=C2N=C(C=C2C)C)B(F)F;1.0;;;10uM;;;; (from review);PMID17346156;;BCRP;1
2645;Human;Mesalazine;89576;O=C(O)c1cc(ccc1O)N;O=C(O)C1=C(C=CC(=C1)N)O;0.05;(imputed as non-binder from inhibition data);0.0;10uM;0.6-fold increase at 50mkM (106% at 50mkM);Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM),  (from review);P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30;;BCRP;0
2647;Human;Methotrexate;59052;OC(CC[C@H](NC(=O)C1=CC=C(C=C1)N(C)CC2N=C3C(=NC(=NC3=NC=2)N)N)C(O)=O)=O;OC(CC[C@H](NC(=O)C1=CC=C(C=C1)N(C)CC2N=C3C(=NC(=NC3=NC=2)N)N)C(O)=O)=O;1.0;"Km =5.7mM; Km=1.3mM; Km=680mkM";0.0;10uM;"1.5-fold increase at 50mkM (93% at 50mkM); - at 30mkM; 98% at 600mkM";"Mitoxantrone; Estrone 3-sulfate; Estrone 3-sulfate";"membrane vesicle from ABCG2-expressing HEK-293 cell; K562/BCRP cell; P388/BCRP cell; Saos-2/wtABCG2 cells";"uptake (vesicle); Transported only by the Wild-form of BCRP!!; uptake inhibition (33nM [H3]estrone-3-sulfate + 0.5mkM estrone-3-sulfate)";"H. Mitomo, Biochem J (2003) 373, 767-74; Z. S. Chen, Cancer Res (2003) 63, 4048-54; E. L. Volk, Cancer Res (2003) 63, 5538-43; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; Y.Han et al, Eur J Pharm Sci (2008) 35, 30-41; Y. Imai, Mol Pharmacol (2003) 64, 610-8; M. Suzuki, J Biol Chem (2003) 278, 22644-9; PMID17346156";;BCRP;1
2648;Human;Methotrexate-Glu2;41600139;OC(=O)CC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)N(C)CC2=CN=C3C(=N2)C(=NC(=N3)N)N;OC(=O)CC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)N(C)CC2=CN=C3C(=N2)C(=NC(=N3)N)N;1.0; ;;10uM;;;membrane vesicle from ABCG2-R482-expressing HEK293 cell ;uptake (vesicle) ;Z. S. Chen, Cancer Res (2003) 63, 4048-54 ;;BCRP;1
2649;Human;Methotrexate-Glu3;41600140;O=C(O)[C@@H](NC(=O)CC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)N(C)CC2=CN=C3C(=N2)C(=NC(=N3)N)N)CCC(=O)O;O=C(O)[C@@H](NC(=O)CC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)N(C)CC2=CN=C3C(=N2)C(=NC(=N3)N)N)CCC(=O)O;1.0; ;;10uM;;;membrane vesicle from ABCG2-R482-expressing HEK293 cell ;"SYN: NSC 341076; uptake (vesicle) ";Z. S. Chen, Cancer Res (2003) 63, 4048-54 ;;BCRP;1
2650;Human;Methotrexate-Glu4;82925153;O=C(O)[C@@H](NC(=O)CC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)N(C)CC2=CN=C3C(=N2)C(=NC(=N3)N)N)CCC(=O)N[C@H](C(O)=O)CCC(=O)O;O=C(O)[C@@H](NC(=O)CC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)N(C)CC2=CN=C3C(=N2)C(=NC(=N3)N)N)CCC(=O)N[C@H](C(O)=O)CCC(=O)O;0.0;;;10uM;;;membrane vesicle from ABCG2-R482-expressing HEK293 cell ;uptake (vesicle) ;Z. S. Chen, Cancer Res (2003) 63, 4048-54 ;;BCRP;0
2654;Human;Mitoxantrone;65271809;O=C2c1c(c(NCCNCCO)ccc1NCCNCCO)C(=O)c3c2c(O)ccc3O;O=C1C3=C(C(C2=C1C(=CC=C2NCCNCCO)NCCNCCO)=O)C(=CC=C3O)O;1.0;Kact=7mkM ;0.0;10uM;"50% at 50mkM; IC50=61mkM";"Methotrexate; Estrone 3-sulfate";membrane vesicle from BCRP-expressing Sf9 cell;"ATP hydrolysis; substrate of both, mutant and wild-type forms";"C. Ozvegy, Biochem Biophys Res Commun (2001) 285, 111-7; E. L. Volk, Cancer Res (2003) 63, 5538-43; M. Suzuki, J Biol Chem (2003) 278, 22644-9; Y.Han et al, Eur J Pharm Sci (2008) 35, 30-41; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;1
2655;Human;MK-571;86840;O=C(N(C)C)CCSC(SCCC(=O)O)c1cccc(c1)\C=C\c2nc3cc(Cl)ccc3cc2;O=C(N(C)C)CCSC(SCCC(=O)O)C1=CC(=CC=C1)C(/[H])=C(/[H])C2=CC=C3C=CC(=CC3=N2)[Cl];0.2;(likely inactive);0.5;10uM;IC50=50mkM (30% at 50mkM);Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone accumulation;"W. Brand et al, Biomedicine & Pharmacotherapy 60 (2006) 508-519; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;0
2662;Human;NB-506;151069124;O=CNN1C(=O)c2c(C1=O)c3c4cccc(O)c4Nc3c5c2c6cccc(O)c6N5C7OC(CO)C(O)C(O)C7O;O=CNN1C(C2=C(C1=O)C5=C(C3NC4=C(C=CC=C4C2=3)O)N(C6=C(C=CC=C56)O)C7C(C(C(C(O7)CO)O)O)O)=O;1.0;+ ;;10uM;;;LY and LY/NR2 cell ;intracellular accumulation ;H. Komatani, Cancer Res (2001) 61, 2827-32 ;;BCRP;1
2666;Human;NH125 (2-methyl imidazolium iodide derivative);278603080;CCCCCCCCCCCCCCCC[N+]1=C(C)N(Cc2ccccc2)C=C1.[I-];CCCCCCCCCCCCCCCC[N+]1C=CN(C=1C)CC2=CC=CC=C2;0.05;(imputed as non-binder from inhibition data);0.0;10uM; - at 50mkM;Methotrexate;"A2780-Dx cell; MCF-7 cell ";increase in Methotrexate intracellular accumulation (MTX: 1mkm);S. Arora, Mol Pharmacol (2004) 66, 460-7 ;;BCRP;0
2673;Human;NSC-23925;19287559;COc1ccc(cc1)c2nc3ccccc3c(c2)C(O)C4CCCCN4;COC1=CC=C(C=C1)C2=CC(=C3C=CC=CC3=N2)C(O)C4NCCCC4;0.1; - [by inference];0.0;10uM; - at 10mkM;Calcein-AM;;drug resistance;Z.Duan et al, PLoS One (2009) 4(10), e7415;;BCRP;0
2674;Human;NX211;149882100;O=C1[C@](C2C=C3N(C(C=2CO1)=O)CC4C(=C5C=C6OCCOC6=CC5=NC3=4)CN7CCN(CC7)C)(O)CC;O=C1[C@](C2C=C3N(C(C=2CO1)=O)CC4C(=C5C=C6OCCOC6=CC5=NC3=4)CN7CCN(CC7)C)(O)CC;1.0; + (weaker than of irinotecan);;10uM;;;T8 and MX3 cell ;drug resistance;"M. Maliepaard, Clin Cancer Res (2001) 7, 935-41; PMID17346156";;BCRP;1
2677;Human;Ortataxel;186348232;O=C(OC(C)(C)C)N[C@@H](CC(C)C)[C@@H](O)C(=O)O[C@@H]2C(=C4/[C@@H](OC(=O)C)C(=O)[C@]6([C@H]([C@H](OC(=O)c1ccccc1)[C@@]3(OC(=O)O[C@@H]23)C4(C)C)[C@@]5(OC(=O)C)[C@H](OC5)C[C@@H]6O)C)/C;O=C(OC(C)(C)C)N[C@@H](CC(C)C)[C@@H](O)C(=O)O[C@H]2[C@@H]6OC(O[C@@]16[C@H]([C@H]3[C@@](C([C@@H](/C(C1(C)C)=C2/C)OC(=O)C)=O)([C@H](C[C@@H]4[C@@]3(CO4)OC(=O)C)O)C)OC(=O)C5=CC=CC=C5)=O;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of 3mkM mitoxantrone ;"PMID17346156; H. Minderman, Cancer Chemother Pharmacol (2004) 53, 363-9; Brooks TA et al, Anticancer Research (2004) 24, 409-416";;BCRP;0
2679;Human;Oxfendazole;53716500;O=S(c2cc1c(nc(n1)NC(=O)OC)cc2)c3ccccc3;O=S(C1=CC=C2C(=C1)N=C(N2)NC(=O)OC)C3=CC=CC=C3;1.0; + (moderate substrate);0.0;10uM;"70% at 100mkM (60% at 250mkM, 0% at 375mkM); 0% at 375mkM";"Mitoxantrone; PhIP";BCRP-expressing MDCKII cells ;transepithelial transport (10mkM), transport inhibition (PhIP 2mkM, Mitoxantrone 5mkM);G. Merino, Drug Metab Dispos (2005) , 33(5), 614-618;;BCRP;1
2680;Human;Paclitaxel;33069624;O=C(N[C@@H](c1ccccc1)[C@@H](O)C(=O)O[C@H]5C[C@@]6(O)[C@@H](OC(=O)c2ccccc2)[C@H]3[C@@](C)([C@@H](O)C[C@H]4OC[C@@]34OC(C)=O)C(=O)[C@H](OC(C)=O)\C(=C5/C)[C@]6(C)C)c7ccccc7;O=C(N[C@@H](C1=CC=CC=C1)[C@@H](O)C(=O)O[C@@H]2C(\C)=C3/[C@H](C([C@@]5([C@H]([C@@H]([C@@](C2)([C@]3(C)C)O)OC(=O)C4=CC=CC=C4)[C@]6(CO[C@@H]6C[C@@H]5O)OC(C)=O)C)=O)OC(C)=O)C7=CC=CC=C7;0.0;;0.2;10uM;(likely inactive);; ;"SYN: Taxol; (from review)";"P.Borst et al, J.Nat.Cancer Inst 92 (2000) 1295-1302; PMID17346156";;BCRP;0
2681;;Pantoprazole;102625707;FC(F)Oc3cc1c(nc(n1)S(=O)Cc2nccc(OC)c2OC)cc3;FC(F)OC1=CC=C2C(=C1)N=C(N2)S(=O)CC3=C(C(=CC=N3)OC)OC;1.0;Km=0.1-0.2mM ;1.0;10uM;IC50=13mkM;methotrexate;Bcrp-expressing MDCKII cell ;transepithelial transport ;P. Breedveld, Cancer Res (2004) 64, 5804-11 ;;BCRP;1
2684;Human;Pheophorbide alpha;6056888;O=C(O)CCC1C(C)C(N=C12)=CC3=C(C)C(C(C)O)=C(N3)C=C4C(C)=C(CC)C(=N4)C=C5C(C)=C6C(N5)=C2CC6=O;O=C(O)CCC1C6=NC(C1C)=CC2NC(=C(C=2C)C(C)O)C=C3N=C(C(=C3C)CC)C=C4NC5C(=C4C)C(CC=56)=O;1.0; + (def);;10uM;;;MDCKII-BCRP;transport inhibition;"PMID17346156; J.Weiss et al, J Antimicrob Chemother(2007), 59(2), 238-245";;BCRP;1
2687;Human;Phosphatidylserine;8002435;CCCCCC=CCC=CCCCCCCCC(OC(COC(CCCCCCCC=CCC=CCCCCCC)=O)COP(O)(OCCN(C)(C)C)=O)=O;CCCCCC=CCC=CCCCCCCCC(OC(COC(CCCCCCCC=CCC=CCCCCCC)=O)COP(O)(OCC[N+](C)(C)C)=O)=O;1.0;;;10uM;;;; (from review);PMID17346156;;BCRP;1
2688;;Phytoporphyrin;26359433;O=C(O)CCC=6c2nc(cc5c(c(c(cc1c(c(c(n1)cc\3nc4c2CC(=O)\C4=C/3C)CC)C)n5)CC)C)C=6C;O=C(O)CCC1=C(C2=NC1=C5C6=NC(=CC4=C(C(=C(C=C3C(=C(C(=C2)N3)C)CC)N4)C)CC)C(=C/6C(=O)C5)/C)C;1.0;;;10uM;;;; (from review);PMID17346156;;BCRP;1
2691;Human;Pitavastatin;147511691;O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(c3ccccc3nc1C2CC2)c4ccc(F)cc4;O=C(O)C[C@H](O)C[C@H](O)/C=C(\[H])C1C(=NC3=CC=CC=C3C=1C2=CC=C(C=C2)F)C4CC4;1.0;Km=5.73mkM;1.0;10uM;Ki=2.92mkM;Estrone-3-sulfate;HEK293/BCRP membrane vesicles, MDCKII/BCRP;uptake, transport inhibition (via ATPase activity);M.Hirano et al, Mol Pharm (2005) 68(3), 800-7;;BCRP;1
2693;Human;Pravastatin (acid);81093370;O=C(O)C[C@H](O)C[C@H](O)CC[C@H]2[C@H](/C=C\C1=C\[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@@H]12)C;O=C(O)C[C@H](O)C[C@H](O)CC[C@@H]1[C@H]2[C@H](C[C@@H](\C=C/2C(/[H])=C/[C@@H]1C)O)OC(=O)[C@@H](C)CC;1.0;(+) ;0.0;10uM;"76% at 1000mkM; 0.8-fold increase at 50mkM (102% at 50mkM); Ki > 300mkM";"Estrone-3-sulfate; Mitoxantrone; Estrone-3-sulfate";"OATP1B1/BCRP double transfected MDCKII cell; Saos-2/wtABCG2 cells; HEK293/BCRP membrane vesicles";"Transepithelical Transport (basal to apical); ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM)";"S. Matsushima, J Pharmacol Exp Ther (2005) 314, 1059-67; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31; M. Suzuki, J Biol Chem (2003) 278, 22644-9; M.Hirano et al, Mol Pharm (2005) 68(3), 800-7";;BCRP;1
2694;Human;Prazosin;19216569;O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)c4occc4;O=C(N1CCN(CC1)C2=NC(=C3C=C(C(=CC3=N2)OC)OC)N)C4=CC=CO4;1.0;Kact=1mkM ;0.5;10uM;5.7-fold increase at 50mkM (32% at 50mkM), IC50=36mkM;Mitoxantrone;"membrane vesicle from BCRP-expressing Sf9 cell; Saos-2/wtABCG2 cells";"ATP hydrolysis; Mitoxantrone (1mkM) accumulation (fold increase, at 50mkM)";"C. Ozvegy, Biochem Biophys Res Commun (2001) 285, 111-7; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;1
2698;Human;Progesterone;57830;O=C4\C=C2/[C@]([C@H]1CC[C@@]3([C@@H](C(=O)C)CC[C@H]3[C@@H]1CC2)C)(C)CC4;O=C4C(/[H])=C3/[C@@]([C@@H]1[C@H]([C@@H]2CC[C@@H]([C@@]2(CC1)C)C(=O)C)CC3)(C)CC4;1.0;;0.5;10uM;4.9-fold increase at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;"ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM); ATPase assay ";T. Janvilisri, J Biol Chem (2003) 278, 20645-51 ;;BCRP;1
2703;Human;Quercetin-4'-glucoside;20229565;O=C1C(O)=C(Oc2cc(O)cc(O)c12)c4ccc(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)CO)c(O)c4;O=C1C4=C(C=C(C=C4OC(=C1O)C2=CC(=C(C=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O;0.2;(likely inactive);0.2;10uM;(likely inactive);;; (from review);W. Brand et al, Biomedicine & Pharmacotherapy 60 (2006) 508-519;;BCRP;0
2707;Human;Resveratrol;501360;Oc2cc(\C=C\c1ccc(O)cc1)cc(O)c2;OC1=CC(=CC(=C1)C(/[H])=C(/[H])C2=CC=C(C=C2)O)O;0.2;(likely inactive);0.0;10uM; - at 10mkM;SN-38;K562/BCRP;transport inhibition, drug resistance;"W. Brand et al, Biomedicine & Pharmacotherapy 60 (2006) 508-519; K.Katayama et al, Cancer Chemother Pharmacol (2007) 60, 789-797";;BCRP;0
2708;Human;Rhodamine 123;62669709;COC(=O)C1=C(C=CC=C1)C2=C4C=CC(C=C4OC3=CC(=CC=C23)N)=N;COC(=O)C1=C(C=CC=C1)C2=C4C=CC(C=C4OC3=CC(=CC=C23)N)=N;1.0;Kact=4.5mkM ;;10uM;;;membrane vesicle from BCRP-expressing Sf9 cell ;"ATP hydrolysis; NB transported by mutant R482T protein only (e.g. MCF7 cells)!";"C. Ozvegy, Biochem Biophys Res Commun (2001) 285, 111-7; Y.Han et al, Eur J Pharm Sci (2008) 35, 30-41";;BCRP;1
2711;Human;Robinetin;490313;O=C1c3c(OC(=C1O)c2cc(O)c(O)c(O)c2)cc(O)cc3;O=C1C(=C(OC2=C1C=CC(=C2)O)C3=CC(=C(C(=C3)O)O)O)O;0.2;(likely inactive);0.2;10uM;(likely inactive);;; (from review);W. Brand et al, Biomedicine & Pharmacotherapy 60 (2006) 508-519;;BCRP;0
2712;Human;Rosuvastatin;287714414;O=S(=O)(N(C1=NC(=C(C(=N1)C2=CC=C(C=C2)F)C(/[H])=C\[C@@H](O)C[C@@H](O)CC(=O)O)C(C)C)C)C;O=S(=O)(N(C1=NC(=C(C(=N1)C(C)C)C(/[H])=C\[C@@H](O)C[C@@H](O)CC(=O)O)C2=CC=C(C=C2)F)C)C;1.0;" + ; Km=10.1mkM; Km=2mkM (high affinity) and Km=60.9mkM (low affinity) for two-site model";1.0;10uM;Ki=15.4mkM;Estrone-3-sulfate;"HEK293/BCRP membrane vesicles; MDCKII-BCRP; CRP-expressing HEK293 vesicles and MDCKII/BCRP";transport inhibition, uptake;"L.Zhang et al, Mol. Pharm (2006), 3(1) 62-69; M.Hirano et al, Mol Pharm (2005) 68(3), 800-7; J.W.Deng et al,Pharm Res(2008), 25(8), 1807-14; S.Kitamura et al, Drug Metab Dispos(2008), 36(10), 2014-23";;BCRP;1
2717;Human;Simvastatin (lactone);79902639;O=C(O[C@@H]1[C@H]3C(=C/[C@H](C)C1)\C=C/[C@@H]([C@@H]3CC[C@H]2OC(=O)C[C@H](O)C2)C)C(C)(C)CC;O=C(O[C@H]1C[C@H](/C=C2C(/[H])=C/[C@@H]([C@@H]([C@@H]1/2)CC[C@@H]3C[C@H](CC(O3)=O)O)C)C)C(C)(C)CC;1.0; +;0.5;10uM;"3.9-fold increase at 50mkM (36% at 50mkM); Ki=18mkM";"Mitoxantrone; Estrone-3-sulfate";"Saos-2/wtABCG2 cells; HEK293/BCRP membrane vesicles";ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM);"P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; M.Hirano et al, Mol Pharm (2005) 68(3), 800-7";;BCRP;1
2718;Human;SN-22;78287271;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cccc5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=CC=C4)CC)/[C@](C(OC\5)=O)(O)CC;0.0;3.5-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;0
2719;Human;SN-343;124622737;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cc(C)cc5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=CC(=C4)C)CC)/[C@](C(OC\5)=O)(O)CC;0.0;2.4-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;0
2720;Human;SN-348;124622726;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cc([Br])cc5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=CC(=C4)[Br])CC)/[C@](C(OC\5)=O)(O)CC;0.0;2.9-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;0
2723;Human;SN-352;124622793;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)ccc([Cl])c5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=C(C=C4)[Cl])CC)/[C@](C(OC\5)=O)(O)CC;0.0;2.6-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;0
2724;Human;SN-353;124622782;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)ccc(F)c5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=C(C=C4)F)CC)/[C@](C(OC\5)=O)(O)CC;0.0;3.6-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;0
2725;Human;SN-355;124623047;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)ccc(O)c5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=C(C=C4)O)CC)/[C@](C(OC\5)=O)(O)CC;1.0;105-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;1
2726;Human;SN-364;124652693;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cc([Cl])c([Cl])c5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=C(C(=C4)[Cl])[Cl])CC)/[C@](C(OC\5)=O)(O)CC;0.0;2.0-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;0
2727;Human;SN-38 (7-ethyl-10-hydroxycamptothecin);86639523;O=C1C5=C(C=C2N1CC3C(=C4C(=NC2=3)C=CC(=C4)O)CC)[C@@](C(OC5)=O)(O)CC;O=C1C5=C(C=C2N1CC3C(=C4C(=NC2=3)C=CC(=C4)O)CC)[C@@](C(OC5)=O)(O)CC;1.0;Km=4mkM ;1.0;10uM;IC50=1.6mkM (60% at 10mkM, 40% at 20mkM);Estrone 3-sulfate;"membrane vesicle from PC-6/SN2-5H; membrane vesicle from BCRP-expressing K562 cell";uptake ;"K. Nakatomi, Biochem Biophys Res Commun (2001) 288, 827-32; M. Suzuki, J Biol Chem (2003) 278, 22644-9; Y. Imai, Mol Pharmacol (2003) 64, 610-8";;BCRP;1
2728;Human;SN-38 glucuronide;121080635;O=C2OCC=1C(=O)N6/C(=C\C=1[C@@]2(O)CC)c5nc4c(cc(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)cc4)c(c5C6)CC;O=C1[C@@](C2C(\[H])=C3N(C(C=2CO1)=O)CC4C(=C5C(=NC/3=4)C=CC(=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O)CC)(O)CC;1.0;Km=26mkM ;;10uM;;;membrane vesicle from PC-6/SN2-5H ;uptake ;K. Nakatomi, Biochem Biophys Res Commun (2001) 288, 827-32 ;;BCRP;1
2729;Human;SN-392;124622760;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cc(N)cc5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=CC(=C4)N)CC)/[C@](C(OC\5)=O)(O)CC;1.0;55-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;1
2730;Human;SN-397;124622997;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cc(OC)c(F)c5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=C(C(=C4)OC)F)CC)/[C@](C(OC\5)=O)(O)CC;0.8;13-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;1
2731;Human;SN-398;124623003;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cc(O)c(F)c5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=C(C(=C4)O)F)CC)/[C@](C(OC\5)=O)(O)CC;1.0;213-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;1
2732;Human;SN-443;162472813;O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CC)cc(C)c(F)c5;O=C1C5=C(C(\[H])=C2N1CC3C(=C4C(=NC/2=3)C=C(C(=C4)C)F)CC)/[C@](C(OC\5)=O)(O)CC;0.0;1.8-fold resistance;;10uM;;;BCRP-expressing PC-6 cell ;uptake ;M. Yoshikawa, Int J Cancer (2004) 110, 921-7 ;;BCRP;0
2734;Human;Sotalol;3930209;O=S(=O)(Nc1ccc(cc1)C(O)CNC(C)C)C;O=S(=O)(NC1=CC=C(C=C1)C(O)CNC(C)C)C;0.05;(imputed as non-binder from inhibition data);0.0;10uM;100% at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM);P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30;;BCRP;0
2736;Human;Sulfasalazine;599791;O=S(=O)(Nc1ccccn1)c3ccc(/N=N/c2cc(C(O)=O)c(O)cc2)cc3;O=S(=O)(NC1=NC=CC=C1)C2=CC=C(C=C2)/N=N/C3=CC=C(C(=C3)C(O)=O)O;1.0;Km=0.7mkM (pH=7.0) and Km=0.66mkM (pH=5.5);0.0;10uM;0.4-fold increase at 50mkM (108% at 50mkM);Mitoxantrone;"Saos-2/wtABCG2 cells; BCRP-expressing Sf9 vesicles";ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM);"P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; M.Jani et al, Biol Pharm Bull (2009), 32(30), 497-9";;BCRP;1
2739;Human;Tamoxifen;10540291;CCC(=C(c1ccccc1)c2ccc(OCCN(C)C)cc2)c3ccccc3;CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3;1.0;;0.5;10uM;"1.02-fold increase at 3mkM (weak interaction [Sugimoto]); 3.8-fold increase at 50mkM (36% at 50mkM); - at 30mkM";"SN-38; Mitoxantrone; Topotecan";"membrane vesicle from BCRP-expressing Lactococcus lactis cell; Saos-2/wtABCG2 cells; K562/BCRP cell";"ATPase assay; ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM)";"T. Janvilisri, J Biol Chem (2003) 278, 20645-51; Y. Sugimoto, Mol Cancer Ther (2003) 2, 105-12; PMID17346156; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30";;BCRP;1
2764;Human;Taurocholate;145426;O=S(=O)(O)CCNC(=O)CC[C@@H](C)[C@H]4CC[C@H]3[C@H]2[C@@H]([C@@]1([C@@H](C[C@H](O)CC1)C[C@H]2O)C)C[C@H](O)[C@@]34C;O=S(=O)(O)CCNC(=O)CC[C@@H](C)[C@@H]1[C@@]2([C@H](C[C@H]3[C@H]([C@@H]2CC1)[C@@H](C[C@H]4[C@]3(CC[C@H](C4)O)C)O)O)C;0.0; - at 0.5mkM [Suzuki];0.9;10uM;"70% at 10mkM (75% at 30mkM); 107% at 150mkM; 100% at 50mkM";"Estrone 3-sulfate; Estrone 3-sulfate; Mitoxantrone";"membrane vesicle from BCRP-expressing K562 cell; P388/BCRP cell; Saos-2/wtABCG2 cells";"inhibition of E1S uptake; ABCG2 (BCRP) Mitoxantrone accumulation";"Y. Imai, Mol Pharmacol (2003) 64, 610-8; M. Suzuki, J Biol Chem (2003) 278, 22644-9; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;0
2766;Human;Taurolithocholate-3-sulfate;15324659;O=S(=O)(O)CCNC(=O)CC[C@H]([C@H]1CCC2[C@]1(C)CCC4C2CC[C@@H]3C[C@H](OS(=O)(=O)O)CC[C@@]34C)C;O=S(=O)(O)CCNC(=O)CC[C@H]([C@@H]1[C@@]2(C(CC1)C3C(CC2)[C@]4(CC[C@H](C[C@H]4CC3)OS(=O)(=O)O)C)C)C;0.0; - at 0.5mkM [Suzuki];0.5;10uM;IC50=37mkM (30% at 30mkM);Estrone 3-sulfate;"membrane vesicle from BCRP-expressing K562 cell; P388/BCRP cell";inhibition of E1S ;"Y. Imai, Mol Pharmacol (2003) 64, 610-8; M. Suzuki, J Biol Chem (2003) 278, 22644-9; M. Suzuki, J Biol Chem (2003) 278, 22644-9";;BCRP;0
2767;Human;Tectochrysin;520285;COc1cc(O)c2C(=O)C=C(Oc2c1)c3ccccc3;COC1=CC2OC(=CC(C=2C(=C1)O)=O)C3=CC=CC=C3;0.0; - [by ATPase];1.0;10uM;IC50=3mkM;Mitoxantrone;HEK293-transfected cells;drug resistance;"PMID17346156; A.Ahmed-Belkacem et al, Cancer Res (2005), 65(11), 4852-60";;BCRP;0
2768;Human;Teniposide;29767202;COc8cc(C5C1C(COC1=O)C(OC2OC3COC(OC3C(O)C2O)C4SC=CC=4)c6cc7OCOc7cc56)cc(OC)c8OC;COC1=C(C(=CC(=C1)C2C7C=C8OCOC8=CC=7C(C3C2C(OC3)=O)OC4C(C(C5OC(OCC5O4)C6=CC=CS6)O)O)OC)OC;1.0;;;10uM;;;BCRP-expressing MEF3.8 cell ;drug resistance ;J. D. Allen, Cancer Res (2003) 63, 1339-44 ;;BCRP;1
2771;Human;Testosterone;58220;O=C4\C=C2/[C@]([C@H]1CC[C@@]3([C@@H](O)CC[C@H]3[C@@H]1CC2)C)(C)CC4;O=C4C(/[H])=C3/[C@@]([C@@H]1[C@H]([C@@H]2CC[C@@H]([C@@]2(CC1)C)O)CC3)(C)CC4;1.0;;0.0;10uM;94% at 50mkM;Mitoxantrone;"membrane vesicle from BCRP-expressing Lactococcus lactis cell; Saos-2/wtABCG2 cells";"ATPase assay; ABCG2 (BCRP) Mitoxantrone accumulation";"T. Janvilisri, J Biol Chem (2003) 278, 20645-51; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;1
2773;Human;Tetrandrine;518343;O(c7c(OC)cc4c5c7Oc1cc2c(cc1OC)CCN(C)[C@H]2Cc6ccc(Oc3cc(ccc3OC)C[C@@H]5N(C)CC4)cc6)C;O(C1=C2C7=C(C=C1OC)CCN([C@H]7CC6=CC(OC5C=CC(C[C@@H]4N(CCC3C4=CC(O2)=C(C=3)OC)C)=CC=5)=C(C=C6)OC)C)C;0.1; - [by inference];0.0;10uM; - at 10mkM;Calcein-AM;;"drug resistance; SYN: NSC 77037";M.Susa et al, J Biomol Screen (2010) ASAP;;BCRP;0
2777;Human;Timolol;26839758;O[C@H](COc1nsnc1N2CCOCC2)CNC(C)(C)C;O[C@H](COC1C(=NSN=1)N2CCOCC2)CNC(C)(C)C;0.05;(imputed as non-binder from inhibition data);0.0;10uM;0.9-fold increase at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM);P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30;;BCRP;0
2780;Human;Topotecan;123948878;Oc2ccc3nc4C5=CC1=C(COC(=O)C1(O)CC)C(=O)N5Cc4cc3c2CN(C)C;OC1C(=C2C=C3CN4C(C5=C(C=C4C3=NC2=CC=1)C(C(OC5)=O)(O)CC)=O)CN(C)C;1.0;" + ; Km=213mkM";;10uM;;;"Bcrp1-expressing LLC-PK1 cell; MDCKII-BCRP";transepithelial transport (basal to apical) ;"J. W. Jonker, J Natl Cancer Inst (2000) 92, 1651-6; PMID17346156; H.Li et al, Pharm Res(2008), 25(11), 2601-12";;BCRP;1
2782;;tRA01015;0;C1[C@]([C@@H](OC(=O)c5cc(OC)ccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC(=C2)OC)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=CC=C7)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2783;Human;tRA01069;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)OC(=O)c7ccc(OC)c8c7cccc8)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)OC(=O)C7=C8C(=C(C=C7)OC)C=CC=C8)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];0.0;10uM; - at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2784;Human;tRA9-1a;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccc(N(CC)CC)cc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=C(C=C7)N(CC)CC)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of 3mkM mitoxantrone ;I.Ojima et al, J Med Chem (2003) 48(6), 2218-28;;BCRP;0
2785;Human;tRA9-2a;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccc(OCC)cc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=C(C=C7)OCC)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of 3mkM mitoxantrone ;I.Ojima et al, J Med Chem (2003) 48(6), 2218-28;;BCRP;0
2786;Human;tRA95069;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6cc7ccccc7cc6)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1O;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C7C=CC=CC7=C6)OC(C)=O)O)(C)C)C)O;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2787;Human;tRA96023;204580007;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=CC=C7)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of 3mkM mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2788;Human;tRA97013;0;O=C6OC1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc8ccc(cc8)C(=O)c7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O6)C(C)(C)C4=C(C)[C@H]1OC(=O)C;O=C1O[C@]23C(O1)[C@@H](C(=C(C2(C)C)[C@H](C([C@@]6(C([C@@H]3OC(=O)C4=CC=CC=C4)[C@]5(CO[C@@H]5C[C@@H]6OC(=O)C=CC7=CC=C(C=C7)C(=O)C8=CC=CC=C8)OC(C)=O)C)=O)OC(C)=O)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2789;Human;tRA97045;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccc(F)cc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=C(C=C7)F)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];0.0;10uM; - at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2790;Human;tRA98005;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(c8c6)C(=O)c7c8cccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC8=C(C=C6)C(=O)C7=CC=CC=C78)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2791;Human;tRA98006;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccc(N(C)C)cc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=C(C=C7)N(C)C)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM (2-fold increase at 0.1mkM);Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;"T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205; I.Ojima et al, J Med Chem (2003) 48(6), 2218-28";;BCRP;0
2792;Human;tRA98007;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccc(OC)cc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=C(C=C7)OC)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM (2.8-fold increase at 0.1mkM);Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;"T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205; I.Ojima et al, J Med Chem (2003) 48(6), 2218-28";;BCRP;0
2793;Human;tRA98009;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccc(C(C)C)cc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=C(C=C7)C(C)C)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2794;Human;tRA98010;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)c7ccc(C)cc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)C7=CC=C(C=C7)C)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];0.0;10uM; - at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2795;Human;tRA99010;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)Oc7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)OC7=CC=CC=C7)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2796;Human;tRA99011;0;O=C6OC1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc8ccc(cc8)Oc7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O6)C(C)(C)C4=C(C)[C@H]1OC(=O)C;O=C1O[C@]23C(O1)[C@@H](C(=C(C2(C)C)[C@H](C([C@@]6(C([C@@H]3OC(=O)C4=CC=CC=C4)[C@]5(CO[C@@H]5C[C@@H]6OC(=O)C=CC7=CC=C(C=C7)OC8=CC=CC=C8)OC(C)=O)C)=O)OC(C)=O)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2797;Human;tRA99018;0;O=C6OC1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc8ccc(cc8)NC(=O)c7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O6)C(C)(C)C4=C(C)[C@H]1OC(=O)C;O=C1O[C@]23C(O1)[C@@H](C(=C(C2(C)C)[C@H](C([C@@]6(C([C@@H]3OC(=O)C4=CC=CC=C4)[C@]5(CO[C@@H]5C[C@@H]6OC(=O)C=CC7=CC=C(C=C7)NC(=O)C8=CC=CC=C8)OC(C)=O)C)=O)OC(C)=O)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM (1.6-fold increase at 0.1mkM);Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;"T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205; T.Brooks et al, Anticancer Research (2004) 24, 409-416; I.Ojima et al, J Med Chem (2003) 48(6), 2218-28";;BCRP;0
2798;Human;tRA99019;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)NC(=O)c7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)NC(=O)C7=CC=CC=C7)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM (2.6-fold increase at 0.1mkM);Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;"T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205; T.Brooks et al, Anticancer Research (2004) 24, 409-416";;BCRP;0
2799;Human;tRA99020;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)c6ccc(cc6)C(=O)c7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C6=CC=C(C=C6)C(=O)C7=CC=CC=C7)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM (1.25-fold increase at 0.1mkM);Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;"T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205; I.Ojima et al, J Med Chem (2003) 48(6), 2218-28";;BCRP;0
2800;Human;tRA99021;0;O=C6OC1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)c8ccc(cc8)C(=O)c7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O6)C(C)(C)C4=C(C)[C@H]1OC(=O)C;O=C1O[C@]23C(O1)[C@@H](C(=C(C2(C)C)[C@H](C([C@@]6(C([C@@H]3OC(=O)C4=CC=CC=C4)[C@]5(CO[C@@H]5C[C@@H]6OC(=O)C7=CC=C(C=C7)C(=O)C8=CC=CC=C8)OC(C)=O)C)=O)OC(C)=O)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2801;Human;tRA99030;0;C1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc6ccc(cc6)C(=O)Oc7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O)C(C)(C)C4=C(C)[C@H]1OC(=O)C;C1[C@@H](C(=C5C([C@]1([C@@H](OC(=O)C2=CC=CC=C2)C4[C@]3(CO[C@@H]3C[C@@H]([C@]4(C)C([C@@H]5OC(C)=O)=O)OC(=O)C=CC6=CC=C(C=C6)C(=O)OC7=CC=CC=C7)OC(C)=O)O)(C)C)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2802;Human;tRA99031;0;O=C6OC1[C@]([C@@H](OC(=O)c5ccccc5)C([C@@](CO2)(OC(C)=O)[C@H]2C[C@@H]3OC(=O)C=Cc8ccc(cc8)C(=O)Oc7ccccc7)[C@]3(C)C([C@@H]4OC(C)=O)=O)(O6)C(C)(C)C4=C(C)[C@H]1OC(=O)C;O=C1O[C@]23C(O1)[C@@H](C(=C(C2(C)C)[C@H](C([C@@]6(C([C@@H]3OC(=O)C4=CC=CC=C4)[C@]5(CO[C@@H]5C[C@@H]6OC(=O)C=CC7=CC=C(C=C7)C(=O)OC8=CC=CC=C8)OC(C)=O)C)=O)OC(C)=O)C)OC(=O)C;0.0; - [Brooks TA];1.0;10uM; + at 10mkM;Mitoxantrone;8226/MR20 cells;efflux of mitoxantrone ;T.Brooks et al, Molecular Cancer Therapeutics (2003) 1195-1205;;BCRP;0
2803;Human;Triamcinolone acetonide;76255;O=C1C=C5[C@@](C=C1)(C)[C@]2(F)[C@H]([C@H]3[C@](C[C@@H]2O)([C@@]4(OC(O[C@@H]4C3)(C)C)C(=O)CO)C)CC5;O=C1C=C5[C@@](C=C1)(C)[C@]2(F)[C@H]([C@H]3[C@](C[C@@H]2O)([C@@]4(OC(O[C@@H]4C3)(C)C)C(=O)CO)C)CC5;0.0; - at 5mkM [by ATPase];0.0;10uM; - at 10mkM;Mitoxantrone;MCF7/MR cells;efflux inhibition (5mkM of Mitoxantrone, 40min time);H.Cooray et al, European Journal of Pharmacology (2006) 531, 25-33;;BCRP;0
2808;Human;Verapamil;52539;COc2cc(CCN(C)CCCC(C(C)C)(C#N)c1ccc(OC)c(OC)c1)ccc2OC;COC1=C(C=CC(=C1)CCN(C)CCCC(C(C)C)(C#N)C2=CC(=C(C=C2)OC)OC)OC;0.2;(likely inactive);0.5;10uM;"IC50>50mkM; 4.1-fold increase at 50mkM (29% at 50mkM)";"Hoechst 33342; Mitoxantrone";"BCRP-expressing Sf9 cell; Saos-2/wtABCG2 cells";"efflux of Hoechst33342; ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM)";"C. Ozvegy-Laczka, Mol Pharmacol (2004) 65, 1485-95; P.Matsson et al, J Pharmacol Exp Ther(2007), 323(1), 19-30; PMID17346156";;BCRP;0
2809;Human;Vinblastine;865214;CC(=O)OC5C(O)(C8N(C)c9cc(OC)c(C3(CC4CN(CCC1=C3Nc2ccccc12)CC(O)(CC)C4)C(OC)=O)cc9C78CCN6CC=CC5(CC)C67)C(OC)=O;CC(=O)OC1C8(C=CCN9CCC2(C3C=C(C(=CC=3N(C2C1(O)C(OC)=O)C)OC)C4(C6=C(CCN5CC(C4)CC(C5)(O)CC)C7=CC=CC=C7N6)C(OC)=O)C89)CC;0.0;;0.0;10uM;101% at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone accumulation;"PMID17346156; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;0
2810;Human;Vincristine;57227;O=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C=O)[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]7(/C=C\CN([C@@H]78)CC9)CC;O=C(OC)[C@]1(C[C@H]4C[C@](CN(CCC2=C1NC3=CC=CC=C23)C4)(O)CC)C5=CC6=C(C=C5OC)N([C@@H]7[C@]69[C@H]8N(C\C=C/[C@@]8([C@H]([C@@]7(O)C(=O)OC)OC(=O)C)CC)CC9)C=O;1.0;;0.0;10uM;101% at 50mkM;Mitoxantrone;"BCRP-expressing MEF3.8 cell; Saos-2/wtABCG2 cells";"drug resistance; ABCG2 (BCRP) Mitoxantrone accumulation";"J. D. Allen, Cancer Res (2003) 63, 1339-44; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31";;BCRP;1
2814;Human;Zidovudine;30516871;CC2C(=O)NC(=O)N(C1CC(C(CO)O1)N=N#N)C=2;CC1=CN(C(NC1=O)=O)C2OC(C(C2)N=N#N)CO;1.0;;0.0;10uM;"0.9-fold increase at 50mkM (102% at 50mkM); - at 10-100mkM (+ at 500mkM)";"Mitoxantrone; Pheophorbide alpha";"Saos-2/wtABCG2 cells; MDCKII-BCRP";"Cytotoxicity; ABCG2 (BCRP) Mitoxantrone accumulation (fold increase, at 50mkM); Pheophorbide (1mkM, 1h preincubation) flow cytometry efflux inhibition";"X. Wang, Mol Pharmacol (2003) 63, 65-72; PMID17346156; P.Matsson et al, Pharm Res(2009), 26(8), 1816-31; J.Weiss et al, J Antimicrob Chemother(2007), 59(2), 238-245";;BCRP;1
2837;Human;Valsartan;137862534;O=C(O)[C@@H](N(C(=O)CCCC)Cc3ccc(c1ccccc1c2nnnn2)cc3)C(C)C;O=C(O)[C@@H](N(C(=O)CCCC)CC1=CC=C(C=C1)C2=C(C=CC=C2)C3N=NNN=3)C(C)C;0.0;" - (by overall transport) [Young]; - [Yamashiro]";;10uM;;;"Caco-2 cell; OATP1B1/BCRP-transfected MDCKII cells";"transport inhibition; transport studies (Valsartan 0.1mkM)";"A.M.Young et al, J Pharmaceut Sci (2006) 95, 717-25; W.Yamashiro et al, Drug Mteab Dispos (2006), 34(7), 1247-1254";;BCRP;0
2838;Human;Olmesartan (acid);144689247;OC(=O)c2c(nc(n2Cc5ccc(c4ccccc4c3nnnn3)cc5)CCC)C(O)(C)C;OC(=O)C1N(C(=NC=1C(O)(C)C)CCC)CC2=CC=C(C=C2)C3=C(C=CC=C3)C4N=NNN=4;0.0; -;;10uM;;;BCRP-expressing LLC-PK1 vesicles;transport (Olmesartan 0.3mkM);A.Yamada et al, Drug Metab Dispos (2007), 35(12), 2166-2176;;BCRP;0
2839;Human;Olmesartan medoxomil;144689634;O=C1OC(=C(O1)C)COC(=O)c2c(nc(n2Cc5ccc(c4ccccc4c3nnnn3)cc5)CCC)C(O)(C)C;O=C1OC(=C(O1)COC(=O)C2N(C(=NC=2C(O)(C)C)CCC)CC3=CC=C(C=C3)C4=C(C=CC=C4)C5N=NNN=5)C;1.0; +;;10uM;;;BCRP-expressing LLC-PK1 vesicles;transport (Olmesartan medoxomil 9.56mkM);A.Yamada et al, Drug Metab Dispos (2007), 35(12), 2166-2176;;BCRP;1
2840;Human;Adefovir (PMEA);106941257;O=P(O)(O)COCCn1c2ncnc(c2nc1)N;O=P(O)(O)COCCN1C=NC2=C(N=CN=C12)N;0.0; -;;10uM;;;BCRP-expressing HEK293 vesicles;Adefovir uptake (0.1mkM);T.Imaoka et al, Mol Pharmacol (2007), 71(2), 619-627;;BCRP;0
2841;Human;Cidofovir;113852372;O=C1N=C(C=CN1C[C@H](OCP(=O)(O)O)CO)N;O=C1N=C(C=CN1C[C@H](OCP(=O)(O)O)CO)N;0.0; -;;10uM;;;BCRP-expressing HEK293 vesicles;"SYN: (S)-HPMPC; Cidofovir uptake (0.1mkM)";T.Imaoka et al, Mol Pharmacol (2007), 71(2), 619-627;;BCRP;0
2842;Human;Tenofovir;147127206;O=P(O)(O)CO[C@H](C)Cn1c2ncnc(c2nc1)N;O=P(O)(O)CO[C@H](C)CN1C=NC2=C(N=CN=C12)N;0.0; -;0.0;10uM; - at 10-1000mkM;Pheophorbide alpha;"BCRP-expressing HEK293 vesicles; MDCKII-BCRP";"SYN: PMPA; Tenofovir uptake (0.1mkM); Pheophorbide (1mkM, 1h preincubation) flow cytometry efflux inhibition";"T.Imaoka et al, Mol Pharmacol (2007), 71(2), 619-627; J.Weiss et al, J Antimicrob Chemother(2007), 59(2), 238-245";;BCRP;0
2843;Human;Hematoporphyrin;14459291;CC(O)C1C2C=C5NC(=CC4=NC(=CC3NC(C=C(C=1C)N=2)=C(C=3CCC(O)=O)C)C(CCC(O)=O)=C4C)C(=C5C)C(C)O;CC(O)C1C2C=C5NC(=CC4=NC(=CC3NC(C=C(C=1C)N=2)=C(C=3CCC(O)=O)C)C(CCC(O)=O)=C4C)C(=C5C)C(C)O;1.0;Km=17.8mkM;;10uM;;;BCRP-expressing Sf9 vesicles;;A.Tamura et al, Mol Pharmacol (2006), 70(1), 287-96;;BCRP;1
2844;Human;Belotecan;256411322;O=C1N4C(=CC2=C1COC(=O)[C@]2(O)CC)c3nc5c(c(c3C4)CCNC(C)C)cccc5;O=C1C5=C(C=C2N1CC3C(=C4C(=NC2=3)C=CC=C4)CCNC(C)C)[C@@](C(OC5)=O)(O)CC;0.8;Km>0.5mM;;10uM;;;Caco-2 and MDCKII-BCRP cells;transport;H.Li et al, Pharm Res(2008), 25(11), 2601-12;;BCRP;1
2852;Human;Emtricitabine;143491570;FC=1C(=NC(=O)N(C=1)[C@H]2O[C@H](SC2)CO)N;FC=1C(=NC(=O)N(C=1)[C@H]2O[C@H](SC2)CO)N;0.05;(imputed as non-binder from inhibition data);0.0;10uM; - at 10-1000mkM;Pheophorbide alpha;MDCKII-BCRP;Pheophorbide (1mkM, 1h preincubation) flow cytometry efflux inhibition;J.Weiss et al, J Antimicrob Chemother(2007), 59(2), 238-245;;BCRP;0
2853;Human;Stavudine;3056175;O=C1C(=CN(C(=O)N1)[C@@H]2O[C@@H](C=C2)CO)C;O=C1C(=CN(C(=O)N1)[C@@H]2O[C@@H](C=C2)CO)C;0.05;(imputed as non-binder from inhibition data);0.0;10uM; - at 50-1000mkM;Pheophorbide alpha;MDCKII-BCRP;Pheophorbide (1mkM, 1h preincubation) flow cytometry efflux inhibition;J.Weiss et al, J Antimicrob Chemother(2007), 59(2), 238-245;;BCRP;0
2854;Human;Didanosine;69655056;O=C3N=CNC1=C3N=CN1[C@@H]2O[C@@H](CC2)CO;O=C3N=CNC1=C3N=CN1[C@@H]2O[C@@H](CC2)CO;0.05;(imputed as non-binder from inhibition data);0.0;10uM; - at 10-500mkM;Pheophorbide alpha;MDCKII-BCRP;Pheophorbide (1mkM, 1h preincubation) flow cytometry efflux inhibition;J.Weiss et al, J Antimicrob Chemother(2007), 59(2), 238-245;;BCRP;0
2855;Human;Zalcitabine;7481892;O=C1N=C(N)C=CN1[C@@H]2O[C@@H](CC2)CO;O=C1N=C(N)C=CN1[C@@H]2O[C@@H](CC2)CO;0.05;(imputed as non-binder from inhibition data);0.0;10uM; - at 10-1000mkM;Pheophorbide alpha;MDCKII-BCRP;Pheophorbide (1mkM, 1h preincubation) flow cytometry efflux inhibition;J.Weiss et al, J Antimicrob Chemother(2007), 59(2), 238-245;;BCRP;0
2928;Human;CHEMBL600469;0;CO\C(=C/c1ccc(O)cc1)C(=O)O;CO\C(=C/c1ccc(O)cc1)C(=O)O;0.05;(imputed as non-binder from inhibition data);0.0;10uM;IC50>100mkM;Pheophorbide alpha;NCI-H460/MX20;Inhibition of PhA efflux (fluorescence);K.Takada et al, Bioorg Med Chem Lett(2010), 20(4), 1330-3;;BCRP;0
3004;Human;p-Aminohippurate;94166;O=C(c1ccc(N)cc1)NCC(=O)O;O=C(C1=CC=C(C=C1)N)NCC(=O)O;0.05;(imputed as non-binder from inhibition data);0.0;10uM;100% at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone (1mkM) accumulation;P.Matsson et al, Pharm Res(2009), 26(8), 1816-31;;BCRP;0
3009;Human;Cefamandole;34444014;O=C2N1C(=C(CS[C@@H]1[C@@H]2NC(=O)[C@H](O)c3ccccc3)CSc4nnnn4C)C(=O)O;O=C1[C@H]([C@H]2SCC(=C(N12)C(=O)O)CSC3N(N=NN=3)C)NC(=O)[C@H](O)C4=CC=CC=C4;0.05;(imputed as non-binder from inhibition data);0.0;10uM;102% at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone (1mkM) accumulation;P.Matsson et al, Pharm Res(2009), 26(8), 1816-31;;BCRP;0
3013;Human;Flucloxacillin;5250395;O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1c(F)cccc1Cl)C)[C@H]4SC3(C)C;O=C(O)[C@H]1C(S[C@@H]2[C@@H](C(N12)=O)NC(=O)C3C(=NOC=3C)C4=C(C=CC=C4F)[Cl])(C)C;0.05;(imputed as non-binder from inhibition data);0.0;10uM;100% at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone (1mkM) accumulation;P.Matsson et al, Pharm Res(2009), 26(8), 1816-31;;BCRP;0
3016;Human;Phenobarbital;50066;O=C1NC(=O)NC(=O)C1(c2ccccc2)CC;O=C1C(C(NC(N1)=O)=O)(C2=CC=CC=C2)CC;0.05;(imputed as non-binder from inhibition data);0.0;10uM;101% at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone (1mkM) accumulation;P.Matsson et al, Pharm Res(2009), 26(8), 1816-31;;BCRP;0
3020;Human;Valproate;99661;OC(=O)C(CCC)CCC;OC(=O)C(CCC)CCC;0.05;(imputed as non-binder from inhibition data);0.0;10uM;101% at 50mkM;Mitoxantrone;Saos-2/wtABCG2 cells;ABCG2 (BCRP) Mitoxantrone (1mkM) accumulation;P.Matsson et al, Pharm Res(2009), 26(8), 1816-31;;BCRP;0
3021;Human;Ethinylestradiol-3-sulfate;24560701;O=S(=O)(O)Oc1cc4c(cc1)[C@H]3CC[C@]2([C@@H](CC[C@]2(C#C)O)[C@@H]3CC4)C;O=S(=O)(O)OC1=CC=C2C(=C1)CC[C@@H]3[C@H]4[C@@](CC[C@H]23)([C@](CC4)(C#C)O)C;1.0;Km1= 2.9mkM and Km2=307mkM;;10uM;;;Sf9-BCRP membrane vesicles;uptake studies of EE2-Sul (0.01-200mkM);Y-H.Han et al, Drug Metab Dispos (2010) 38(7), 10721082;;BCRP;1
3022;Human;Sepantronium;781661947;[Br-].O=C1c3c(C(=O)c2c1cccc2)[n+](c(n3CCOC)C)Cc4nccnc4;O=C1C4=C(C(C2=C1N(C(=[N+]2CC3=CN=CC=N3)C)CCOC)=O)C=CC=C4;0.0; - at 100mkM;;10uM;;;LLC-BCRP membrane vesicles;"uptake of YM155 (100mkM); SYN: YM155";M.Iwai et al , Drug Metab Dispos (2011) 39(12), 2314-20;;BCRP;0
